...
首页> 外文期刊>American Journal of PharmTech Research >Optimization and Evaluation of Acyclovir Loaded Liquid and Solid Self Nanoemulsifying Drug Delivery System
【24h】

Optimization and Evaluation of Acyclovir Loaded Liquid and Solid Self Nanoemulsifying Drug Delivery System

机译:阿昔洛韦载液和固体自纳米乳化递药系统的优化与评价

获取原文

摘要

ABSTRACT Acyclovir has low bioavailability mainly due to low solubility. In this study, solid self-nanoemulsifying drug delivery systems (S-SNEDDS) of acyclovir were developed with the objective of improving its solubility. Initial screening was carried out to select the excipients. Ternary phase diagrams were constructed to detect the nanoemulsification region. The nanoemulsion systems selected from the phase diagram were characterized for their robustness to dilution and cloud point temperature. Box- Behnken design was then applied for further optimization. The formulations obtained were further characterized for their droplet size and entrapment efficiency. The best formulation was converted to S-SNEDDS by simple adsorption technique. The liquid SNEDDS (L-SNEDDS) was adsorbed onto microcrystalline cellulose in 1:1 ratio. Zeta potential, differential scanning calorimetry, scanning electron microscopy was then carried out. In vitro drug release was studied by comparing the S-SNEDDS with pure drug. The L-SNEDDS formulation which was converted to S-SNEDDS showed particle size of 147 nm. The formulation was found to be robust to dilution and showed cloud point at 86 ◦C. Negative zeta potential meant, there was no coalescence of globules. SEM studies of nanoemulsion demonstrated that the globules in L-SNEDDS were indeed adsorbed on the MCC. Results of DSC confirmed that the drug was incorporated in the S-SNEDDS that was formulated. The in vitro drug release from acyclovir S-SNEDDS was found to be considerably higher in comparison to that of the pure drug. Therefore, it can be concluded that acyclovir loaded S-SNEDDS improved the solubility and release characteristics of the drug. Keywords: Acyclovir, Self nanoemulsifying drug delivery systems (SNEDDS), Box-Behnken design, Powder SNEDDS
机译:摘要阿昔洛韦的生物利用度低,主要原因是溶解度低。在这项研究中,开发了阿昔洛韦固体自纳米乳化药物递送系统(S-SNEDDS),旨在提高其溶解度。进行初步筛选以选择赋形剂。构造三元相图以检测纳米乳化区域。从相图中选择的纳米乳液系统具有对稀释和浊点温度的稳健性。然后将Box-Behnken设计应用于进一步的优化。获得的制剂的液滴尺寸和截留效率进一步表征。最好的配方通过简单的吸附技术转化为S-SNEDDS。液体SNEDDS(L-SNEDDS)以1:1的比例吸附到微晶纤维素上。然后进行Zeta电位,差示扫描量热法,扫描电子显微镜。通过将S-SNEDDS与纯药物进行比较,研究了体外药物释放。转化为S-SNEDDS的L-SNEDDS制剂显示出147nm的粒径。发现该制剂对稀释具有鲁棒性,并在86℃下显示浊点。负ζ电势意味着,没有小球的聚结。纳米乳液的SEM研究表明,L-SNEDDS中的小球确实吸附在MCC上。 DSC的结果证实了该药物被掺入所配制的S-SNEDDS中。与纯药物相比,从阿昔洛韦S-SNEDDS的体外药物释放被发现要高得多。因此,可以得出结论,载有阿昔洛韦的S-SNEDDS可改善药物的溶解度和释放特性。关键字:阿昔洛韦,自纳米乳化药物递送系统(SNEDDS),Box-Behnken设计,粉末SNEDDS

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号